Shattuck Labs, Inc.
- Last sale
- Nov 12, 2026 · -4.67%
- Market cap
- $488.34M
- 101.84M shares
- Filings
- 415
Q3 2026−82.5% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−5.6% FY25 yoy
- $488.34M
- —
- —
- 2.5×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,000,000 | reported | |
| FY 2024 | 2024-12-31 | $5,721,000 | reported | |
| FY 2023 | 2023-12-31 | $1,657,000 | reported | |
| FY 2022 | 2022-12-31 | $652,000 | reported | |
| FY 2021 | 2021-12-31 | $30,017,000 | reported | |
| FY 2020 | 2020-12-31 | $9,934,000 | reported | |
| FY 2019 | 2019-12-31 | $9,887,000 | reported |
Segments
Products
LineFY2025ShareChange
Related party license revenue$1.00M100%—
Collaboration revenue:$0.00—−100.0%
Total$1.00M
Pharmaceutical preparations
Shattuck Labs, Inc. is the 216th largest of the 552 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
NRXPNRX Pharmaceuticals, Inc.$1.2M—2,336.5%$97.6MLGVNLongeveron Inc.$1.2M49.9%1,893.6%$404.1KBLRXBioLineRx Ltd.$1.2M95.9%171.7%—NEUPNeuphoria Therapeutics Inc.$1.2M92.5%1,145.7%$14.0MSXTCChina SXT Pharmaceuticals, Inc.$1.1M34.6%545.2%$2.6MSXTP60 Degrees Pharmaceuticals, Inc.$1.0M65.5%732.5%$581.6K
STTKShattuck Labs, Inc. (this company)$1.0M82.5%4,880.9%$488.3M
RFLRafael Holdings, Inc.$874.0K4.7%3,390.7%$57.9MRLYBRallybio Corp$858.0K34.9%1,046.4%$84.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Shattuck Labs, Inc. · CIK 1680367 · Engraved from SEC EDGAR